Clinical trials: Cerebral Small Vessels Disease
Cerebral Small Vessel Disease
Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease
In healthy people, blood flow to particular areas in the brain increases when the area becomes more active. This ensures that the brain gets enough blood at the right place and time.
- Trial name
- NCT06643013
- Testing
- XBD173
- Where
- United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Fabry Disease
Sophisticated Assessment of Disease Burden in Patients With Fabry Disease
To detect early signs of cardiac and metabolic alterations as well as to evaluate the progression of cardiac and metabolic impairments in mildly affected patients with Fabry Disease using high sensitive diagnostic methods.
- Trial name
- SOPHIA (NCT01210196)
- Testing
- MRI
- Where
- 11 sites in Belgium, Czechia and 4 more
- Volunteers
- 36 people
- Sponsor
- Shire
Lacunar Stroke
The Relationship Between Controlling Risk Factors and Cerebral Haemodynamics in Lacunar Stroke
The goal of this observational study is to look at differences in brain blood flow before and after management of risk factors such as high blood pressure and diabetes in patients with lacunar stroke.
- Trial name
- LACUNAR_CA (NCT06354881)
- Testing
- Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Leicester
Small Vessel Cerebrovascular Disease
Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial
Chronic damage to small blood vessels deep in the brain is seen in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and almost half of patients with…
- Trial name
- OxHARP (NCT03855332)
- Testing
- Sildenafil, Cilostazol
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Oxford
Fabry Disease
Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main questions it aims to answer are: Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients.
- Trial name
- NCT05710367
- Testing
- Dapagliflozin 10mg Tab
- Volunteers
- 46 people
- Sponsor
- Albina Nowak, MD
Fabry Disease
Dosing Study of Replagal in Patients With Fabry Disease
This study will determine the safety and effectiveness of increasing Replagal infusions in certain patients with Fabry disease. Replagal is a genetically engineered form of Alpha-galactosidase A, an enzyme that normally breaks…
- Trial name
- NCT00068107
- Testing
- Replagal
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Cerebral Small Vessel Diseases
Retinal, Cerebral and Vascular Precursor Markers of Cerebral Small Vessel Disease.
Cognitive impairment and dementia are primarily due to a combination of vascular brain injury and neurodegenerative lesions. The vascular component is now recognized as a major contributor to the pathophysiology of dementia, with…
- Trial name
- SHIVA-SHARE (NCT05305144)
- Testing
- Vascular and ophthalmological examinations
- Where
- France
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Fabry Disease
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
GR181413A/AT1001 (migalastat hydrochloride) is a low molecular weight iminosugar, an analog of the terminal galactose group that is cleaved from the substrate GL-3.
- Trial name
- NCT01853852
- Testing
- GR181413A/AT1001 solution, GR181413A/AT1001 capsule, Potable water
- Where
- Australia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Lacunar Stroke, Small Vessel Cerebrovascular Disease
Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD)
The TELECONNECT-SVD study is a prospective, randomized, multicenter trial aimed at testing the efficacy of a remotely delivered exercise protocol on brain functional connectivity in patients with small vessel disease…
- Trial name
- TELECONNECT (NCT06525987)
- Testing
- Physical activity
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of L'Aquila
Fabry Disease
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
This is an exploratory study to evaluate changes in glycosphingolipid levels and other (exploratory) Fabry disease parameters in male Fabry disease participants who were previously treated with agalsidase alfa (Replagal®) 0.2…
- Trial name
- NCT01650779
- Testing
- Agalsidase beta
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Genzyme, a Sanofi Company
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Fabry Disease, Proteinuria
Paricalcitol in Fabry Disease
Proteinuria is the predominant risk factor for renal disease progression in Fabry disease (FD). When urine protein excretion is controlled to <0.50 g/24 hr, the rate loss of glomerular filtration rate (GFR) is not significantly…
- Trial name
- NCT02090608
- Testing
- Paricalcitol
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Federico II University
Cerebral Small Vessel Disease, Ischemic Stroke
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Edaravone Dexborneol Sublingual Tablets in patients with acute ischemic stroke due to small vessel…
- Trial name
- TASTE-SVD (NCT06674460)
- Testing
- Edaravone Dexborneol Sublingual Tablets
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking Union Medical College Hospital
Fabry Disease
Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients
Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients
- Trial name
- NCT03596398
- Testing
- GLA gene
- Volunteers
- 1,000 people
- Sponsor
- Chiayi Christian Hospital
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203.
- Trial name
- NCT06961344
- Testing
- zagociguat 15mg
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 37 people
- Sponsor
- Tisento Therapeutics
Wegener Granulomatosis, Microscopic Polyangiitis
Vasculitis Illness Perception (VIP) Study
The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa
- Trial name
- NCT02190916
- Where
- United States
- Volunteers
- 707 people
- Sponsor
- University of South Florida
Fabry Disease, Neuropathic Pain
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling peripheral neuropathic pain in patients with Fabry disease, and reducing their use of opioid analgesics.
- Trial name
- NCT01588314
- Testing
- Gabapentin
- Where
- United States
- Sponsor
- University of Minnesota
Fabry Disease, Lysosomal Storage Diseases
A Fabry Disease Gene Therapy Study
This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
- Trial name
- MARVEL1 (NCT04040049)
- Testing
- FLT190
- Where
- 13 sites in United States, Austria and 5 more
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
Stroke, Dementia
Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie)
"Silent" strokes are more frequent than clinical apparent strokes and can be detected noninvasively by MRI-investigations of the brain.
- Trial name
- NCT01126775
- Where
- 2 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- INVADE gGmbH
Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease
Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1
This prospective study will enroll patients younger than 60 years with ischemic white matter lesions (WMIL) and age-matched healthy controls.
- Conditions
- Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease, Vascular Cell Adhesion Molecule-1, VCAM-1
- Trial name
- NCT07128212
- Testing
- Atorvastatin 10 mg daily
- Where
- China
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Suzhou Municipal Hospital of Anhui Province